CA2100466A1 - Unbuffered premixed ranitidine formulation - Google Patents

Unbuffered premixed ranitidine formulation

Info

Publication number
CA2100466A1
CA2100466A1 CA002100466A CA2100466A CA2100466A1 CA 2100466 A1 CA2100466 A1 CA 2100466A1 CA 002100466 A CA002100466 A CA 002100466A CA 2100466 A CA2100466 A CA 2100466A CA 2100466 A1 CA2100466 A1 CA 2100466A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
formulation
ranitidine
composition
premixed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002100466A
Other languages
English (en)
French (fr)
Inventor
Douglas Giles Johnson
Allan Edward Titus
Dennis Jenke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2100466A1 publication Critical patent/CA2100466A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002100466A 1991-11-15 1992-11-12 Unbuffered premixed ranitidine formulation Abandoned CA2100466A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/793,043 US5169864A (en) 1991-11-15 1991-11-15 Unbuffered premixed ranitidine formulation
US7/793,043 1991-11-15

Publications (1)

Publication Number Publication Date
CA2100466A1 true CA2100466A1 (en) 1993-05-16

Family

ID=25158922

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002100466A Abandoned CA2100466A1 (en) 1991-11-15 1992-11-12 Unbuffered premixed ranitidine formulation

Country Status (8)

Country Link
US (2) US5169864A (US06559137-20030506-C00071.png)
EP (1) EP0571575B1 (US06559137-20030506-C00071.png)
JP (1) JPH06505028A (US06559137-20030506-C00071.png)
AU (1) AU654421B2 (US06559137-20030506-C00071.png)
BR (1) BR9205493A (US06559137-20030506-C00071.png)
CA (1) CA2100466A1 (US06559137-20030506-C00071.png)
DE (1) DE69232409T2 (US06559137-20030506-C00071.png)
WO (1) WO1993009775A1 (US06559137-20030506-C00071.png)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
WO1995010274A1 (en) * 1993-10-14 1995-04-20 F.H. Faulding & Co. Limited Aqueous pharmaceutical composition
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5650421A (en) * 1995-03-31 1997-07-22 Baxter International Inc. Premixed famotidine formulation
WO2003055483A1 (fr) * 2001-12-27 2003-07-10 Terumo Kabushiki Kaisha Solution d'injection de famotidine
WO2007022105A2 (en) 2005-08-12 2007-02-22 Rubicon Research Pvt. Ltd. Stable pharmaceutical compositions, processes for making the same, and methods of their use
WO2009091539A1 (en) 2008-01-15 2009-07-23 Environmental Energy Services, Inc. Process for operating a coal-fired furnace with reduced slag formation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021481A (en) * 1969-06-27 1977-05-03 Nyegaard & Co. A/S Amido derivatives of 2,4,6-triiodobenzoic acids containing at least one N-hydroxyalkyl and at least two hydroxyl groups
US4024271A (en) * 1971-03-09 1977-05-17 Smith Kline & French Laboratories Limited Pharmacologically active guanidine compounds
GB1338169A (en) * 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
US3950033A (en) * 1974-02-22 1976-04-13 Wilcox Raymond J Vehicle wheel
CH608189A5 (US06559137-20030506-C00071.png) * 1974-12-13 1978-12-29 Savac Ag
GB1548594A (en) * 1976-06-11 1979-07-18 Nyegaard & Co As Triiodoisophthalic acid amides
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
AU523295B2 (en) * 1978-07-04 1982-07-22 Nycomed Imaging As X-ray contrast agent
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
GB8313217D0 (en) * 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
US4955871A (en) * 1987-04-29 1990-09-11 Path Single-use disposable syringe
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation

Also Published As

Publication number Publication date
US5169864A (en) 1992-12-08
EP0571575A4 (US06559137-20030506-C00071.png) 1994-03-30
US5304571A (en) 1994-04-19
EP0571575A1 (en) 1993-12-01
AU3075192A (en) 1993-06-15
AU654421B2 (en) 1994-11-03
WO1993009775A1 (en) 1993-05-27
JPH06505028A (ja) 1994-06-09
DE69232409T2 (de) 2002-11-07
EP0571575B1 (en) 2002-02-06
DE69232409D1 (de) 2002-03-21
BR9205493A (pt) 1994-04-05

Similar Documents

Publication Publication Date Title
CA1216240A (en) Pharmaceutical composition containing ranitidine
PT79454B (en) Process for preparing ophtalmic formulations of norfloxacin and related antibiotics
KR20050084498A (ko) 아목시실린 및 클라불란산을 함유하는 조성물
KR100195348B1 (ko) 안정한 프로스타글란딘 e1-함유 주사제 조성물
EP1543831A1 (en) Pregabalin composition
CA2100466A1 (en) Unbuffered premixed ranitidine formulation
US20240207278A1 (en) Pharmaceutical compositions of tofacitinib for oral administration
CA1326453C (en) Pharmaceutical composition containing pentamidine
NZ552182A (en) Pharmaceutical composition of piperazine derivatives
JPH115744A (ja) ヒアルロン酸含有の外用水溶液製剤
CA2448083C (en) Liquid preparations of fudosteine
US5451609A (en) Treatment of impotence
WO2005007168A1 (en) A stable clozapine suspension formulation
US11229597B2 (en) Topical doxycycline composition
US20040191326A1 (en) Taste-masking vehicle for coated oxazolidinone particles
EP3735222A1 (en) Liquid compositions of aprepitant
EP3054924A1 (en) Stable pharmaceutical formulations of caspofungin
KR20190078455A (ko) 플루르비프로펜 함유 스프레이 조성물 및 그 제조방법
ES2684594B1 (es) Solución acuosa de ranitidina exenta de etanol
KR0169402B1 (ko) 티아졸리딘 2,4-디카르복실산 아르기닌염(아르기닌티디아시케이트)함유액제 및 그의 제조방법
WO1993006822A1 (en) Trimethoprim oral liquid
ES2238418T3 (es) Solucion acuosa estable de desoxifructosazina.
KR20040041631A (ko) 에카베트 나트륨 수성 용액 제제
Plouffe et al. Cefotaxime: pharmacokinetics and in vitro antibacterial activity of serum and urine in normal human volunteers
KR0177866B1 (ko) 돔페리돈의 가용화 방법 및 이 가용화된 돔페리돈 용액으로 액제를 제조하는 방법

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued